Therefore, we suggest that ELK3 targeting agents, such as transcription factors–proteolysis targeting chimeras, which enable specific targeting and degrading of transcription factors via the ubiquitin-dependent proteasome [53], could be a promising therapeutic strategy for the treatment of PCa harboring SPOP mutations. Here, SPOP is linked to posterior cortical atrophy.